查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863279

病理學人工智慧市場按產品類型、應用、最終用戶和部署模式分類－全球預測（2025-2032年）

Artificial Intelligence in Pathology Market by Product Type, Application, End User, Deployment Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，病理學領域的人工智慧市場規模將達到 3.1613 億美元，複合年成長率為 15.24%。

主要市場統計數據
基準年 2024 1.0158億美元
預計年份：2025年 1.1652億美元
預測年份：2032年 3.1613億美元
複合年成長率 (%) 15.24%

這本引人入勝且權威的介紹概述了人工智慧技術如何重新定義現代醫療保健系統中的診斷病理工作流程、臨床決策支援和檢查室操作。

人工智慧正在改變病理學，使其從主要依賴模擬和顯微鏡的領域轉變數位化、數據豐富的領域，從而補充人類的專業知識並簡化檢查室操作。影像分析、模式識別和預測建模技術的進步，催生了新的診斷工作流程，提高了可重複性，縮短了處理時間，並提取了肉眼無法看到的具有臨床意義的訊號。因此，病理學正從說明形態學發展到量化的、可輔助決策的輸出，並與電子健康記錄和多學科診療路徑整合。

透過數位化流程、演算法分流、監管成熟和夥伴關係主導的創新策略來變革病理學的關鍵轉折點進行簡要分析

病理學領域正經歷多重變革，這些變革正在改變診斷服務的提供、檢驗和商業化方式。首先，臨床工作流程正從分段式的、以切片為基礎的流程轉向整合式數位流程，集中進行影像擷取、標註和分析。這項變革降低了變異性，實現了分散式的第二意見，並透過利用演算法預篩檢和優先排序提高了病例處理速度。因此，病理學家花費在複雜解讀任務和臨床討論上的時間比例顯著高於常規檢測。

對2025年美國關稅趨勢對人工智慧病理技術採購成本、供應鏈和實施策略的影響進行嚴格評估

預計2025年實施的關稅將對人工智慧病理解決方案的採用和商業化產生多方面的影響。其中一個直接影響通路是資本設備和硬體投入。進口影像系統和專用掃描儀關稅的提高將增加醫院和實驗室的購買成本，促使採購部門重新評估整體擁有成本。這將導致他們優先考慮更長的生命週期管理或國內採購。供應商可能會透過增加本地組裝、重新設計產品物料清單以減少對高關稅部件的依賴以及轉向允許區域客製化的模組化架構來應對。

一種主導細分市場的全面觀點，將產品類型、用例、最終用戶需求和部署模式與實際的採用和整合方案進行繪製。

市場區隔為理解影響病理學人工智慧需求的各種臨床和商業性需求提供了一個實用的框架。按產品類型分類，市場分為「服務」與「解決方案」。服務包括專業服務和培訓支持，因為成功的人工智慧實施需要為病理學家和技術人員提供諮詢、整合和持續教育。解決方案分為硬體和軟體，硬體包括成像掃描器和計算設備。軟體進一步細分為數據分析軟體、全切片成像系統功能以及用於協調病例流轉和報告的工作流程管理軟體。

區域洞察：美洲、歐洲、中東、非洲和亞太地區在採用促進因素、法規結構和商業模式方面的差異，以及這些差異如何說明採用策略。

區域趨勢正在影響三大主要區域（美洲、歐洲、中東和非洲以及亞太地區）的技術應用、監管預期和夥伴關係模式。在美洲，對高通量、精準專家評審和臨床檢測支援的需求正在加速整合醫療系統和大型實驗室對數位病理學和人工智慧的採用。法規環境強調臨床療效和資料隱私，而商業模式通常將資本投資與以金額為準的服務協議結合。因此，供應商正在優先考慮互通性和可靠的證據生成，以滿足不同機構的需求。

企業層面的關鍵發現凸顯了專業供應商、硬體製造商、雲端服務供應商和臨床合作夥伴在病理學人工智慧領域塑造競爭優勢和成功部署方面所發揮的作用。

人工智慧病理診斷領域的競爭格局複雜，既有專業軟體供應商，也有影像硬體製造商、系統整合商、雲端服務供應商以及學術和臨床聯盟。專業軟體供應商通常強調演算法效能、臨床檢驗研究以及與實驗室資訊系統的無縫整合，以此作為差異化優勢。影像硬體製造商則在掃描器吞吐量、影像保真度和與全切片成像標準的兼容性方面展開競爭，而系統整合商則專注於端到端實作、服務等級協定以及檢查室工作流程最佳化。

為臨床領導者和供應商提供切實可行的優先建議，以加速人工智慧病理診斷解決方案的檢驗應用、提升醫護人員的技能水平並實現穩健的商業化。

產業領導者應以清晰的分階段策略來推進病理學領域的人工智慧應用，以平衡臨床檢驗、互通性和營運準備。首先，應優先發展臨床夥伴關係，以進行前瞻性檢驗研究並將其整合到現有診斷流程中。這些研究應旨在證明人工智慧在診斷準確性、週轉時間和患者管理方面的附加價值。其次，應採用模組化架構，將影像擷取和分析分離，使機構能夠在現有硬體上試用軟體功能，同時保持根據需要升級掃描器或將運算遷移到雲端的靈活性。

透明的混合方法調查方法結合了臨床訪談、實施案例研究和技術評估，檢驗實際實施結果。

這些研究結果基於混合方法，整合了質性訪談、臨床案例研究和系統性技術評估。主要研究包括與執業病理學家、檢查室主任、IT架構師和行業高管進行深入訪談，以了解實際實施過程中遇到的挑戰、採購決策促進因素以及臨床檢驗預期。來自實施點的案例研究揭示了試驗計畫中發現的通用整合模式、變革管理策略以及可衡量的營運改善。

該策略結論重點強調了將人工智慧的潛力轉化為病理學中檢驗的臨床工作流程、營運效率和以患者為中心的永續結果的實際步驟。

病理學中的人工智慧不再只是實驗室輔助工具，而是正在成為現代診斷服務不可或缺的一部分，它能夠提高診斷準確性、加快工作流程，並在臨床診療和檢查中創造新的提案。全切片影像、雲端分析和經過嚴格檢驗的預測模型相結合，為病理學開闢了一條拓展臨床應用範圍至預後和治療方案製定的途徑，同時還能確保病患安全和資料管治的嚴格標準。然而，要充分發揮這一潛力，需要的不僅是優秀的演算法；還需要與檢查室工作流程進行周密獎勵、持續的臨床檢驗以及能夠協調相關人員方利益的適應性經營模式。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將可解釋人工智慧技術整合到病理演算法中，以提高臨床醫生的信心並促進監管合規性。
  • 利用人工智慧驅動的多重免疫組化分析量化腫瘤微環境生物標記物，以實現個人化癌症治療
  • 技術供應商與病理檢查室建立策略合作夥伴關係，以實現人工智慧驅動的診斷成像解決方案的商業化。
  • 建立聯邦學習框架，利用多樣化的病患資料集，安全地進行病理學人工智慧模型的多機構訓練
  • 訂閱式軟體即服務 (SaaS) AI 工具的出現，正在使中小檢查室也能進行先進的病理分析。
  • 引入即時人工智慧全切片成像掃描儀，提高了術中會診和數位冰凍切片診斷的效率。
  • 開發用於跨不同患者群體進行安全、多機構病理學人工智慧模型訓練的聯邦學習平台
  • 人工智慧解決方案提供者與臨床病理檢查室建立策略合作夥伴關係，拓展診斷成像商業化進程。
  • 推出基於訂閱的SaaS平台，為區域性和中型檢查室提供先進的AI病理分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 病理學人工智慧市場（按產品類型分類）

  • 服務
    • 專業服務
    • 培訓和支持
  • 解決方案
    • 硬體
    • 軟體
      • 數據分析軟體
      • 全玻片成像系統
      • 工作流程管理軟體

9. 病理學領域人工智慧市場（按應用分類）

  • 計算病理學
  • 數位病理學
    • 遠距病理診斷
    • 全切片成像
  • 預測分析
    • 預後模型
    • 風險預測
  • 工作流程最佳化
    • 病例分診
    • 資源分配

第10章 病理學人工智慧市場（按最終用戶分類）

  • 診斷實驗室
    • 醫院檢查室
    • 參考檢驗機構
  • 醫院診所
    • 大型醫院
    • 中小型醫院
  • 製藥和生物技術公司
    • 生技Start-Ups
    • 大型製藥企業
  • 研究所
    • 學術研究中心
    • 私人考試機構

第11章 病理學人工智慧市場部署模式

  • 雲
    • 私有雲端
    • 公共雲端
  • 本地部署

第12章 病理學人工智慧市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 病理學人工智慧市場（按群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國病理學人工智慧市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • PathAI, Inc.
    • Indica Labs, Inc.
    • Inspirata, Inc.
    • aetherAI
    • Aiforia Technologies Oyj
    • Akoya Biosciences, Inc.
    • Danaher Corporation
    • Deep Bio, Inc.
    • Evident Corporation
    • F. Hoffmann-La Roche Ltd.
    • Ibex Medical Analytics Ltd.
    • Koninklijke Philips NV
    • LUMEA, Inc.
    • MindPeak GmbH
    • Nucleai Inc.
    • OptraSCAN Inc.
    • Paige.AI, Inc.
    • Proscia Inc.
    • Siemens Healthineers AG
    • Techcyte, Inc.
    • Tempus Labs, Inc.
    • Tribun Health
    • Visikol, Inc. by CELLINK
    • Visiopharm A/S
Product Code: MRR-1730A405FA4B

The Artificial Intelligence in Pathology Market is projected to grow by USD 316.13 million at a CAGR of 15.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 101.58 million
Estimated Year [2025] USD 116.52 million
Forecast Year [2032] USD 316.13 million
CAGR (%) 15.24%

An engaging and authoritative introduction framing how AI technologies are redefining diagnostic pathology workflows, clinical decision support, and laboratory operations for modern healthcare systems

Artificial intelligence is transforming pathology from a largely analogue, microscope-driven specialty into a digitized, data-rich discipline that augments human expertise and streamlines laboratory operations. Advances in image analysis, pattern recognition, and predictive modeling are enabling new diagnostic workflows that improve reproducibility, reduce turnaround time, and surface clinically relevant signals that might be imperceptible to the human eye. As a result, pathology is evolving from descriptive morphology toward quantified, decision-support enabled outputs that integrate with electronic health records and multidisciplinary care pathways.

This transformation reflects convergence across several technical trends: high-resolution whole slide imaging, cloud-enabled compute resources, robust data annotation practices, and regulatory frameworks that increasingly recognize the clinical value of validated algorithms. Consequently, pathology teams are evaluating AI not as a single tool but as an ecosystem of interoperable components that includes hardware, data pipelines, software analytics, and integrated workflows. For leaders, this means that adoption decisions hinge as much on change management, clinical validation, and interoperability as they do on algorithm performance metrics. As institutions pursue digitization and AI-enabled services, the emphasis shifts to measurable clinical outcomes, operational efficiency, and scalable deployment models that align with institutional risk tolerance and reimbursement pathways.

A concise analysis of the transformative shifts reshaping pathology through digital pipelines, algorithmic triage, regulatory maturation, and partnership-driven innovation strategies

The landscape of pathology is undergoing several transformative shifts that collectively reconfigure how diagnostic services are delivered, validated, and commercialized. First, clinical workflows are migrating from fragmented slide-based processes toward integrated digital pipelines that centralize image acquisition, annotation, and analysis. This shift reduces variability, enables distributed second opinions, and accelerates case throughput by leveraging algorithmic pre-screening and prioritization. As a result, pathologists increasingly spend proportionally more time on complex interpretive tasks and clinical discussions rather than routine screening.

Second, the economics of diagnostic services are changing as AI-enabled capabilities create new value levers. Predictive analytics and prognostic models facilitate personalized therapy selection and clinical trial matching, thereby extending pathology's role into treatment planning and translational research. Third, regulatory and reimbursement landscapes are maturing, with authorities placing greater emphasis on clinical validation, post-market surveillance, and explainability. This strengthens deployment confidence but also raises the bar for evidence generation. Fourth, partnerships between technology vendors, healthcare providers, and research institutions are becoming central to innovation, driving co-development models that integrate clinical expertise early in product design. Ultimately, these shifts create a more distributed, interoperable, and clinically integrated pathology ecosystem focused on measurable improvements in diagnostic accuracy, patient outcomes, and laboratory efficiency.

A rigorous assessment of how 2025 United States tariff dynamics can reshape procurement costs, supply chains, and deployment strategies for AI-enabled pathology technologies

Anticipated tariff measures in the United States in 2025 present a multi-dimensional influence on the adoption and commercialization of AI-enabled pathology solutions. One immediate channel of impact is on capital equipment and hardware inputs. Increased duties on imported imaging systems and specialty scanners elevate acquisition costs for hospitals and reference laboratories, prompting procurement teams to re-evaluate total cost of ownership and prioritize either prolonged lifecycle management or domestic sourcing. In turn, suppliers may respond by localizing assembly, redesigning product BOMs to reduce exposure to tariffed components, or shifting to more modular architectures that permit regional customization.

Another consequential effect pertains to supply chain resilience and inventory strategies. Faced with tariff uncertainty, organizations tend to increase buffer stocks, lengthen procurement cycles, and diversify supplier bases, which can delay deployment timelines for digitization initiatives. On the software front, cloud-delivered analytics experience less direct tariff pressure, but indirect effects arise when cloud solutions rely on regulated or tariffed hardware for edge acquisition. Consequently, system integrators will emphasize hybrid deployment architectures that decouple analysis from acquisition and favor software licensing models that mitigate upfront capital exposure.

From an innovation and commercial strategy perspective, tariffs can accelerate regional competitive dynamics by incentivizing local entrants and manufacturing consolidation. Companies with established domestic manufacturing or strong local partnerships gain relative advantage, while export-oriented vendors must adapt pricing or pursue nearshoring. Finally, clinical adoption decisions reflect not only cost but also risk; higher procurement costs can delay investments in clinical validation studies and real-world evidence programs. Therefore, leaders should anticipate tariff-driven shifts in procurement behavior, supply chain design, pricing strategies, and partnership models, and proactively design deployment roadmaps that preserve project momentum despite external trade pressures.

A comprehensive segmentation-driven perspective that maps product types, application priorities, end-user requirements, and deployment modes to practical adoption and integration choices

Segmentation provides a practical framework for understanding how different clinical and commercial needs shape demand for AI in pathology. Under product type, the market divides into Services and Solutions. Services encompass Professional Services and Training & Support, recognizing that successful AI deployments require consulting, integration, and sustained education for pathologists and laboratory staff. Solutions split into Hardware and Software, where Hardware includes imaging scanners and compute appliances and Software fragments further into Data Analysis Software, Whole Slide Imaging System capabilities, and Workflow Management Software that orchestrates case routing and reporting.

Application-level segmentation highlights both diagnostic and operational use cases. Computational Pathology focuses on algorithmic interpretation and feature extraction, while Digital Pathology covers telepathology and whole slide imaging workflows that enable remote review and distributed case sharing. Predictive Analytics emphasizes models such as Prognostic Models and Risk Prediction that extend pathology's role into outcome forecasting. Workflow Optimization captures operational use cases like Case Triage and Resource Allocation that improve lab throughput and prioritize urgent cases.

End-user segmentation underscores where value realization occurs. Diagnostic Laboratories are differentiated between Hospital-Based Labs and Reference Laboratories, each with distinct volume patterns and integration needs. Hospitals & Clinics span Large Hospitals and Small & Mid-Size Hospitals, reflecting differences in IT maturity and procurement cycles. Pharma & Biotech include Biotech Startups and Large Pharma, which leverage pathology AI for biomarker discovery and companion diagnostics, while Research Institutes cover Academic Research Centers and Private Labs that drive translational validation and algorithm training. Finally, deployment mode differentiates Cloud and On-Premise approaches, with Cloud further divided into Private Cloud and Public Cloud options that balance scalability, latency, and data governance preferences. This multi-dimensional segmentation clarifies where technical capabilities, commercialization models, and clinical validation priorities must align to achieve meaningful outcomes.

Actionable regional insights that explain how adoption drivers, regulatory frameworks, and commercial models differ across the Americas, EMEA, and Asia-Pacific and what that means for deployment strategies

Regional dynamics influence technology adoption, regulatory expectations, and partnership models across three principal geographies: the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, digital pathology and AI deployments accelerate in integrated health systems and large reference laboratories, driven by demand for higher throughput, centralized specialist review, and clinical trial support. The regulatory environment emphasizes clinical validation and data privacy, while commercial models often combine capital investment with value-based service agreements. Consequently, vendors tend to prioritize interoperability and robust evidence generation to satisfy diverse institutional requirements.

In Europe, Middle East & Africa, adoption patterns vary significantly by country and healthcare setting, with advanced digital initiatives concentrated in metropolitan centers and academic hubs. Regulatory frameworks emphasize patient data protection and clinical performance, and public procurement processes can shape vendor selection through long lead cycles and tender-based contracts. Meanwhile, the Asia-Pacific region demonstrates rapid uptake in metropolitan hospitals and private labs, supported by investment in digital infrastructure, domestic technology suppliers, and a high appetite for performance-enhancing tools. Across these regions, differences in reimbursement models, local manufacturing capabilities, and regulatory pathways create both challenges and opportunities. Hence regional strategies must adapt product architectures, pricing models, and partnership structures to reconcile local clinical priorities with global development plans.

Key company-level insights revealing how specialized vendors, hardware makers, cloud providers, and clinical partnerships shape competitive advantage and deployment success in pathology AI

Competitive dynamics in AI-enabled pathology reflect a mix of specialized software vendors, imaging hardware manufacturers, systems integrators, cloud service providers, and academic-clinical consortia. Specialized software vendors tend to differentiate on algorithmic performance, clinical validation studies, and seamless integration with laboratory information systems. Imaging hardware manufacturers compete on scanner throughput, image fidelity, and compatibility with whole slide imaging standards, while systems integrators emphasize end-to-end implementation, service-level agreements, and laboratory workflow optimization.

Cloud service providers and managed service operators offer scalable compute and regulatory-compliant hosting options that reduce capital barriers for institutions, and partnerships between technology vendors and clinical centers accelerate real-world validation. Additionally, a growing number of consortium-driven initiatives and startup spinouts are driving niche innovations in areas such as stain normalization, multiplexed tissue analysis, and model explainability. From a strategic standpoint, companies that combine rigorous clinical validation, clear regulatory pathways, and partnership-oriented commercial models gain sustainable advantage. Mergers and acquisitions remain a common route for incumbents to acquire capabilities rapidly, while thoughtful alliances between vendors and clinical networks enable faster deployment and evidence generation. Ultimately, the competitive landscape rewards organizations that balance technical excellence with operational support and a transparent roadmap to clinical impact.

Practical and prioritized recommendations for clinical leaders and vendors to accelerate validated deployment, workforce readiness, and resilient commercialization of AI-powered pathology solutions

Industry leaders should approach AI in pathology with a clear, phased strategy that balances clinical validation, interoperability, and operational readiness. First, prioritize clinical partnerships that enable prospective validation studies and integration into existing diagnostic pathways; these studies should be designed to demonstrate incremental value in diagnostic accuracy, turnaround time, or patient management. Second, adopt modular architectures that decouple image acquisition from analytics so organizations can pilot software capabilities on existing hardware while preserving flexibility to upgrade scanners or migrate compute to the cloud as needed.

Third, invest in workforce readiness through targeted training and continuous education programs that cover model limitations, interpretability, and workflow changes; clinicians who understand how AI augments their decisions accelerate adoption and mitigate unintended consequences. Fourth, align procurement and contracting with total cost of ownership thinking by incorporating software-as-a-service options, performance guarantees, and shared-risk arrangements that reduce upfront capital exposure. Fifth, develop robust data governance and validation frameworks that document training cohorts, performance across demographic groups, and post-deployment monitoring plans. Finally, cultivate diverse partnerships with local manufacturing, academic centers, and clinical networks to increase resilience against supply chain disruptions and regulatory variability. Taken together, these actions position leaders to translate technological potential into reliable clinical and operational outcomes.

A transparent, mixed-method research methodology combining primary clinical interviews, implementation case studies, and technical assessments to validate practical adoption insights

The research underpinning these insights employed a mixed-methods approach that integrates primary qualitative interviews, clinical case studies, and systematic technology assessment. Primary research included in-depth conversations with practicing pathologists, laboratory directors, IT architects, and industry executives to capture real-world implementation challenges, procurement decision drivers, and clinical validation expectations. Case studies drawn from implementation sites illustrate common integration patterns, change management strategies, and measurable operational improvements observed during pilot programs.

Secondary analysis combined peer-reviewed literature, regulatory guidance documents, and publicly available technical white papers to map algorithmic performance characteristics, data governance expectations, and interoperability standards. Technology assessment focused on image acquisition fidelity, algorithm robustness across staining and scanner variability, and workflow orchestration capabilities. Data triangulation validated qualitative findings against technical specifications and regulatory milestones. Throughout, emphasis remained on replicable methods, transparency in evidence sources, and clear delineation between observed practices and emerging trends, ensuring that recommendations are actionable and grounded in clinical realities.

A strategic conclusion emphasizing pragmatic steps to convert AI promise into validated clinical workflows, operational gains, and sustainable patient-centric outcomes in pathology

AI in pathology is no longer an experimental adjunct; it is becoming an integral element of modern diagnostic services that can enhance accuracy, accelerate workflows, and enable new value propositions across clinical care and research. The combination of whole slide imaging, cloud-enabled analytics, and carefully validated predictive models creates a pathway for pathology to expand its clinical remit into prognostication and treatment planning while maintaining rigorous standards for patient safety and data governance. Nevertheless, realizing this potential requires more than superior algorithms; it calls for thoughtful integration with laboratory workflows, sustained clinical validation, and adaptive commercial models that align incentives across stakeholders.

As organizations embrace digitization, priorities should include investing in robust data infrastructure, cultivating clinician buy-in through education and co-development, and designing deployment roadmaps that can withstand supply chain and regulatory variability. By focusing on measurable outcomes and flexible architectures, pathology leaders can convert technological promise into operational value that supports better patient care, faster decision making, and more efficient use of scarce specialist resources. The path forward is iterative: pilot, validate, scale, and monitor-each stage informed by clinical evidence and operational metrics that demonstrate real-world impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of explainable AI techniques within pathology algorithms to boost clinician trust and facilitate regulatory compliance
  • 5.2. Adoption of AI-driven multiplex immunohistochemistry analysis to quantify tumor microenvironment biomarkers for personalized cancer therapies
  • 5.3. Strategic partnerships between technology vendors and pathology laboratories to commercialize AI-driven diagnostic imaging solutions
  • 5.4. Establishment of federated learning frameworks for secure multi-institutional training of pathology AI models on diverse patient datasets
  • 5.5. Introduction of regulatory-approved deep learning algorithms improving prognostic accuracy and reducing diagnostic variability in hematopathology
  • 5.6. Emergence of subscription-based software-as-a-service AI tools democratizing advanced pathology analytics for small and mid-sized laboratories
  • 5.7. Deployment of real-time AI-enabled whole slide image scanners to streamline intraoperative consultations and digital frozen section reviews
  • 5.8. Development of federated learning infrastructures enabling secure multi-center pathology AI model training on diverse patient cohorts
  • 5.9. Strategic alliances between AI solution providers and clinical pathology labs to scale diagnostic imaging commercialization
  • 5.10. Launch of subscription-based SaaS platforms bringing advanced AI pathology analytics to community and mid-size laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Pathology Market, by Product Type

  • 8.1. Services
    • 8.1.1. Professional Services
    • 8.1.2. Training & Support
  • 8.2. Solutions
    • 8.2.1. Hardware
    • 8.2.2. Software
      • 8.2.2.1. Data Analysis Software
      • 8.2.2.2. Whole Slide Imaging System
      • 8.2.2.3. Workflow Management Software

9. Artificial Intelligence in Pathology Market, by Application

  • 9.1. Computational Pathology
  • 9.2. Digital Pathology
    • 9.2.1. Telepathology
    • 9.2.2. Whole Slide Imaging
  • 9.3. Predictive Analytics
    • 9.3.1. Prognostic Models
    • 9.3.2. Risk Prediction
  • 9.4. Workflow Optimization
    • 9.4.1. Case Triage
    • 9.4.2. Resource Allocation

10. Artificial Intelligence in Pathology Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Hospital-Based Labs
    • 10.1.2. Reference Laboratories
  • 10.2. Hospitals & Clinics
    • 10.2.1. Large Hospitals
    • 10.2.2. Small & Mid-Size Hospitals
  • 10.3. Pharma & Biotech
    • 10.3.1. Biotech Startups
    • 10.3.2. Large Pharma
  • 10.4. Research Institutes
    • 10.4.1. Academic Research Centers
    • 10.4.2. Private Labs

11. Artificial Intelligence in Pathology Market, by Deployment Mode

  • 11.1. Cloud
    • 11.1.1. Private Cloud
    • 11.1.2. Public Cloud
  • 11.2. On-Premise

12. Artificial Intelligence in Pathology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Artificial Intelligence in Pathology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Intelligence in Pathology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. PathAI, Inc.
    • 15.3.2. Indica Labs, Inc.
    • 15.3.3. Inspirata, Inc.
    • 15.3.4. aetherAI
    • 15.3.5. Aiforia Technologies Oyj
    • 15.3.6. Akoya Biosciences, Inc.
    • 15.3.7. Danaher Corporation
    • 15.3.8. Deep Bio, Inc.
    • 15.3.9. Evident Corporation
    • 15.3.10. F. Hoffmann-La Roche Ltd.
    • 15.3.11. Ibex Medical Analytics Ltd.
    • 15.3.12. Koninklijke Philips N.V.
    • 15.3.13. LUMEA, Inc.
    • 15.3.14. MindPeak GmbH
    • 15.3.15. Nucleai Inc.
    • 15.3.16. OptraSCAN Inc.
    • 15.3.17. Paige.AI, Inc.
    • 15.3.18. Proscia Inc.
    • 15.3.19. Siemens Healthineers AG
    • 15.3.20. Techcyte, Inc.
    • 15.3.21. Tempus Labs, Inc.
    • 15.3.22. Tribun Health
    • 15.3.23. Visikol, Inc. by CELLINK
    • 15.3.24. Visiopharm A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HARDWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY COMPUTATIONAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY TELEPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PROGNOSTIC MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CASE TRIAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESOURCE ALLOCATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITAL-BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SMALL & MID-SIZE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY BIOTECH STARTUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PREDICTIVE ANALYTICS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY WORKFLOW OPTIMIZATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS ARTIFICIAL INTELLIGENCE IN PATHOLOGY MARKET SIZE, BY PHARMA & BIOTECH, 2018-2024 (USD M